Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) — Tangible Net Worth Ratio
Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) has a Tangible Net Worth Ratio of 70.3% as of March 2026. This metric is calculated by deducting intangible assets (CN¥500.66 Million) from net assets (CN¥1.69 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) net assets for net asset value and shareholders' equity analysis.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Jiangsu Lianhuan Pharmaceutical Co Ltd Tangible Net Worth Ratio (2000–2024)
This chart shows how Jiangsu Lianhuan Pharmaceutical Co Ltd's Tangible Net Worth Ratio has changed across 25 annual periods from 2000 to 2024. As of March 2026, the ratio stands at 70.3%, reflecting net assets of CN¥1.69 Billion with intangible assets of CN¥500.66 Million CNY. Also explore net asset growth rate of Jiangsu Lianhuan Pharmaceutical Co Ltd to track the company's year-over-year net asset growth rate.
Annual Tangible Net Worth Ratio for Jiangsu Lianhuan Pharmaceutical Co Ltd (2000–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for Jiangsu Lianhuan Pharmaceutical Co Ltd from 2000 to 2024, covering 25 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see 600513 stock market capitalisation.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 83.6% | CN¥1.58 Billion | CN¥258.77 Million | CN¥3.02 Billion | ▼ -7.2 pp |
| 2023 | 90.8% | CN¥1.52 Billion | CN¥138.97 Million | CN¥2.86 Billion | ▼ -0.2 pp |
| 2022 | 91.1% | CN¥1.41 Billion | CN¥126.19 Million | CN¥2.71 Billion | ▲ +0.4 pp |
| 2021 | 90.7% | CN¥1.28 Billion | CN¥118.89 Million | CN¥2.35 Billion | ▼ -0.6 pp |
| 2020 | 91.3% | CN¥1.18 Billion | CN¥102.57 Million | CN¥2.05 Billion | ▼ -0.3 pp |
| 2019 | 91.6% | CN¥1.08 Billion | CN¥91.10 Million | CN¥1.89 Billion | ▼ -3.2 pp |
| 2018 | 94.8% | CN¥946.61 Million | CN¥49.53 Million | CN¥1.42 Billion | ▲ +0.0 pp |
| 2017 | 94.7% | CN¥878.23 Million | CN¥46.23 Million | CN¥1.16 Billion | ▼ -0.1 pp |
| 2016 | 94.8% | CN¥827.25 Million | CN¥42.68 Million | CN¥1.07 Billion | ▼ -4.0 pp |
| 2015 | 98.8% | CN¥774.88 Million | CN¥9.05 Million | CN¥1.00 Billion | ▲ +0.0 pp |
| 2014 | 98.8% | CN¥434.25 Million | CN¥5.17 Million | CN¥658.96 Million | ▲ +0.4 pp |
| 2013 | 98.4% | CN¥402.11 Million | CN¥6.41 Million | CN¥649.48 Million | ▲ +0.2 pp |
| 2012 | 98.2% | CN¥350.42 Million | CN¥6.28 Million | CN¥443.21 Million | ▲ +0.5 pp |
| 2011 | 97.7% | CN¥327.61 Million | CN¥7.50 Million | CN¥418.52 Million | ▲ +0.9 pp |
| 2010 | 96.8% | CN¥308.95 Million | CN¥9.88 Million | CN¥401.08 Million | ▲ +0.9 pp |
| 2009 | 95.9% | CN¥293.89 Million | CN¥12.08 Million | CN¥383.36 Million | ▲ +1.0 pp |
| 2008 | 94.9% | CN¥281.68 Million | CN¥14.29 Million | CN¥359.66 Million | ▼ -3.5 pp |
| 2007 | 98.5% | CN¥269.97 Million | CN¥4.13 Million | CN¥357.66 Million | ▲ +0.4 pp |
| 2006 | 98.0% | CN¥259.20 Million | CN¥5.13 Million | CN¥335.84 Million | ▲ +0.4 pp |
| 2005 | 97.6% | CN¥255.97 Million | CN¥6.12 Million | CN¥305.41 Million | ▲ +0.4 pp |
| 2004 | 97.2% | CN¥250.42 Million | CN¥7.11 Million | CN¥312.05 Million | ▲ +0.5 pp |
| 2003 | 96.7% | CN¥246.22 Million | CN¥8.19 Million | CN¥293.21 Million | ▲ +7.3 pp |
| 2002 | 89.3% | CN¥85.26 Million | CN¥9.10 Million | CN¥126.28 Million | ▲ +3.8 pp |
| 2001 | 85.5% | CN¥69.48 Million | CN¥10.09 Million | CN¥115.66 Million | ▲ +4.8 pp |
| 2000 | 80.7% | CN¥55.16 Million | CN¥10.67 Million | CN¥103.67 Million | — |